{"filing":{"accession_number":"0001104659-26-082772","cik":"0001297184","ticker":"AMPH","company_name":"Amphastar Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"amph-20260709x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1297184/000110465926082772/amph-20260709x8k.htm"},"events":[{"id":17430,"run_id":15605,"accession_number":"0001104659-26-082772","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Anthony Pierce as a Class III director effective immediately, approved by the Board on July 9, 2026. While the disclosure also includes compensatory details (annual cash retainer of $55,000 and equity grant of $300,000), the principal action is the appointment itself. The Board expanded the authorized number of directors from 10 to 11 specifically to accommodate this appointment, making the directorship the salient event.","company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":[{"id":15898,"accession_number":"0001104659-26-082772","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Anthony Pierce as a Class III director effective immediately, approved by the Board on July 9, 2026. While the disclosure also includes compensatory details (annual cash retainer of $55,000 and equity grant of $300,000), the principal action is the appointment itself. The Board expanded the authorized number of directors from 10 to 11 specifically to accommodate this appointment, making the directorship the salient event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:05:19.710564+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15898,"accession_number":"0001104659-26-082772","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Anthony Pierce as a Class III director effective immediately, approved by the Board on July 9, 2026. While the disclosure also includes compensatory details (annual cash retainer of $55,000 and equity grant of $300,000), the principal action is the appointment itself. The Board expanded the authorized number of directors from 10 to 11 specifically to accommodate this appointment, making the directorship the salient event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:05:19.710564+00:00","company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","filing_date":"2026-07-13"}]}